Radioactive Preparation Carriers TRIZ Cases

Polyvalent acid trapping enables solid phase extraction purification, eliminating HPLC delays and preserving precursor structure.

Complexing agents bind toxic 212Pb daughter nuclides in 224Ra solutions, reducing off-target toxicity and extending shelf life.

An anti-uPA antibody binds active urokinase-type plasminogen activator to trigger receptor-mediated internalization.

Conjugates comprising immunoglobulin single variable domains labeled with zwitterionic fluorescent moieties exhibit exclusive renal clearance and low serum protein binding.

Fusing an albumin-binding domain with a HER2-targeting peptide prevents renal reabsorption, enhancing tumor delivery.

A multivalent glyco-complex links three glucose molecules to a central nitrogen atom via linkers and a chelating group.

Combining NTSR1-targeted radiopharmaceuticals with DNA damage response inhibitors reduces normal tissue toxicity while enhancing treatment efficacy.

A modified 18F-FACBC synthesis process replaces the alumina cartridge with a hydrophilic lipophilic balanced solid phase for purification.

Bifunctional molecules with tripodal hexadentate tris(hydroxypyridinone) chelators bind radionuclides at room temperature.

Radiolabeled antibodies enable precision dosing based on patient pharmacokinetics, addressing refractory non-Hodgkin lymphoma relapse.

Radiolabeled PSMA inhibitors bind to cancer cells for precise PET/CT signal identification, resolving late-stage anatomical detection limits.

A hydrophobic tag on the leaving group enables simple column chromatography purification of radioactive fluorine-labeled compounds.

Central shielding in a strontium-90 source reduces healthy tissue exposure while maintaining uniform dose distribution.

A PSMA-targeted radiometal conjugate releases a TLR agonist in the tumor microenvironment to activate immune cells.

Chelating agents mediate radionuclide integration into liposomes, preventing leaching and ensuring accurate biodistribution data.

A 211At-labeled amino acid derivative accumulates in cancer cells via LAT1 transport to emit high-energy alpha rays.

An [18F]AlF-labeled PSMA molecular probe utilizes an AlF intermediary complex to achieve high stability and rapid tumor uptake.

Cystine and dissolved oxygen shifts remove heterogeneous caps from antibodies, producing uniform cysteine species for consistent icIEF profiles.

Radiolabeled HER3 agents deliver localized radiation to kill tumor cells without causing receptor downregulation that limits subsequent dosing.

Salicylic acid conjugated PAMAM dendrimers resolve low sensitivity in CEST imaging by generating persistent contrast for brain tumor monitoring.

A modular platform prepares water-soluble prosthetic groups that efficiently introduce 18F into proteins via site-specific conjugation.

Segmented chelator, cytotoxic, and targeting vector modules enable targeted dual nuclear medical cytotoxic theranostics while reducing damage to healthy tissue.

Left-right striatum uptake ratios eliminate camera variability in dopamine transporter imaging, enabling accurate neurological disease diagnosis.

Amphipathic trifunctional peptides form stable lipoprotein complexes that enable targeted delivery of therapeutic agents to specific cellular receptors.

Lanmodulin replaces synthetic chelators to sequester rare earth elements with high selectivity while improving sustainability.

Targeting mitochondrial Complex-1 isolates apoptotic signals from immune activation, enabling early therapeutic effect diagnosis via PET.

Phase-transitioning biopolymers create localized radiation depots that overcome dense stromal barriers and protect healthy tissue.

Fluorinated metal tricarbonyl complexes replace suboptimal tracers by enabling rapid renal excretion and accurate plasma flow estimation.

Segmentation separates the targeting antibody from the radioligand, reducing immunogenicity and clearance time while improving imaging contrast.

Reducing the PSMA I&T to lutetium molar ratio lowers cumulative radiation doses to healthy organs while maintaining radiochemical purity.

Injecting a radioactive solution into tumor tissue induces in situ precipitation of stable isotopes.

Standardized [18F]-FACBC injection protocols resolve low sensitivity issues in prostate cancer detection.

Strained cyclooctyne substrates enable rapid radiometal probe synthesis by eliminating copper interference that blocks conventional click chemistry.

Segmented cationic steroid antimicrobials separate binding domains from labels to prevent interference while maintaining protease resistance.

Segmented molecular structures enable specific targeting of PSMA-expressing tumors while minimizing renal side effects.

Segmented PARP inhibitor conjugates with lysosome-escaping linkers target tumor cells specifically, reducing systemic side effects.

Radiolabeled Affibody molecules enable rapid PET imaging of HER2 expression, replacing invasive biopsies to reduce procedural delays and toxicity risks.

Fluorinated somatostatin derivatives enable rapid radiolabeling with fluorine-18 through isotope exchange reactions.

Segmented anti-hK2 radioconjugates reduce bone marrow toxicity by shortening circulating half-life while maintaining targeting specificity.

Gallium and indium metal complexes facilitate aqueous 18F radiolabelling, avoiding peptide degradation from high temperatures.

Radiolabeled antibodies bind misfolded SOD1 to enable early detection of amyotrophic lateral sclerosis before clinical symptoms manifest.

Optimized 15-minute post-administration timing and 30-minute scan duration resolve signal-to-noise trade-offs for accurate Parkinson's diagnosis.

Novel Tc-99m heteroaryl complexes enable efficient radiolabeling via stable coordination with imidazolyl and pyridyl ligands.

Segmenting polyethylene glycol into monodisperse units eliminates immunogenicity and aggregation while enabling precise pharmacokinetic control.

A CD163 targeting composition enables non-invasive detection of macrophages in atherosclerotic plaques.